GlassScriptPhysician profile
Thomas L Goff
NPI 1376767962
$7,592.43
in general payments reported to CMS, 2019-2025
39 companies · $729 in 2025
The $729 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,427 · 2020: $874 · 2021: $932 · 2022: $927 · 2023: $876 · 2024: $827 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422 · Education: $10.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.54 |
| Education | $10.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,524.37 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $1,013.38 | 2019-2020 | |
| Abiomed | $738.62 | 2019-2024 | Impella |
| Medtronic, INC. | $547.04 | 2023-2025 | Reveal Linq, Onyx Frontier, Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $408.13 | 2020-2025 | Lifevest |
| Pfizer INC. | $390.12 | 2019-2025 | |
| Abbott Laboratories | $376.34 | 2019-2024 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $342.33 | 2019-2025 | |
| Amgen INC. | $289.30 | 2020-2024 | Repatha |
| Boston Scientific Corporation | $287.08 | 2021-2025 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor, Cds - Mct/Cem Monitoring |
| Penumbra, INC. | $157.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $132.74 | 2019-2021 | |
| Amarin Pharma, INC. | $129.08 | 2019-2020 | |
| Esperion Therapeutics, INC. | $125.01 | 2021 | |
| Irhythm Technologies, INC. | $117.79 | 2023-2024 | Zio Xt Patch, Zio Monitor |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $108.08 | 2022-2025 | |
| Gilead Sciences, INC. | $103.98 | 2023-2024 | Veklury |
| Corcept Therapeutics | $101.71 | 2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $97.32 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.15 | 2019-2024 | Camzyos |
| Novo Nordisk INC | $86.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $51.57 | 2022-2025 | Zerbaxa |
| Shockwave Medical, INC | $48.47 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lilly USA, LLC | $32.54 | 2021-2025 | Mounjaro |
| Actelion Pharmaceuticals US, INC. | $29.81 | 2019 | |
| Edwards Lifesciences Corporation | $28.48 | 2025 | Sapien 3 Ultra Resilia |
| Baxter Healthcare | $27.29 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Chiesi USA, INC. | $26.89 | 2020-2021 | |
| Halozyme INC | $24.31 | 2023 | |
| United Therapeutics Corporation | $20.13 | 2025 | Tyvaso |
| Elutia, INC. | $19.13 | 2022 | |
| Atricure, INC. | $16.63 | 2021 | |
| Inspire Medical Systems, INC. | $16.52 | 2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $16.06 | 2023 | Nuzyra |
| Astellas Pharma US INC | $15.56 | 2023 | Cresemba |
| Lundbeck LLC | $13.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.23 | 2020 | |
| Cardiovascular Systems INC. | $9.78 | 2019 | |
| Bardy Diagnostics, INC. | $8.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Goff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.